Receptor for Hyaluronan-Mediated Motility or RHAMM

Share

Hi everyone!

My name is Alexandra Hauser-Kawaguchi and I’m a PhD candidate in the Department of Chemistry at Western University. I work in Dr. Len Luyt’s lab at London Health Sciences Centre’s London Regional Cancer Program.

Alexandra Hauser-Kawaguchi - BCSC Breast Cancer ResearcherFor the past few years, I have been studying the protein RHAMM (Receptor for Hyaluronan-Mediated Motility). RHAMM levels increase in response to fragmentation of the compound hyaluronan (HA), which ultimately results in the spread of cancer and thus poorer outcomes for breast cancer patients.

We have recently been developing stapled peptides as RHAMM mimics. “Stapled” peptides are compounds that have been partially cyclized, giving them the appearance of having a “stapled” backbone. This “stapling” allows the peptide to circulate through the body longer than it would otherwise. This is ideal, as our RHAMM mimics are part of a drug discovery initiative, in which we have shown that they are able to block inflammation associated with breast cancer relating to fragmented HA. The RHAMM mimics could also help stop the disease from spreading to other parts of the body.

In September of 2016, I had the opportunity to attend the 34th European Peptide Symposium and 8th International Peptide Symposium in Leipzig, Germany. I was one of eight chosen to give an oral presentation in front of 700 scientists. This experience was frightening but also thrilling, and the high point of my graduate student career to date. After meeting with and learning from experts in the field, I returned to the lab full of new ideas on how to make our compounds better drugs for treating breast cancer.

Thank you to BCSC for your trainee support!
– Alexandra Hauser-Kawaguchi, PhD candidate
Pamela Greenaway-Kohlmeier Translational Breast Cancer Research Unit, London Health Sciences Centre

Related Articles

Meet Anayra

Anayra Goncalves is a PhD student in the Department of Anatomy & Cell Biology at WesternUniversity. She is conducting BCC-funded breast cancer research under the

Understanding BRCA2

Breast cancer is the most commonly diagnosed cancer among women in Canada. While age remains the strongest risk factor, inherited genetic mutations also play an

Progress Through Research

Latest Research

Breast Cancer Canada donations fund life-saving research that directly impacts Canadian patients. That means better answers, bigger breakthroughs – and more personalized treatment for every breast cancer diagnosis.

Patient Tools

Our suite of digital tools are each designed to help individuals better manage their breast cancer journey through education, research and personalized insights, while also elevating the patient voice.

Patient Stories

Every breast cancer journey is unique, but together, these stories paint a powerful picture of progress. Through firsthand accounts from patients and survivors, we share stories that highlight the lived-experiences of breast cancer.

Fuel Progress

Progress happens when we invest in it. Canada is home to some of the world’s brightest minds in research. Together, we are advancing science, ensuring it leads to earlier detection, better treatments, and improved outcomes for patients across the country.

Sign Up, Know More